Angle (AGL)


AGL Share PerformanceMore

52 week high80.00 15/06/17
52 week low44.00 30/03/17
52 week change -13.50 (-20.15%)
4 week volume5,695,077 25/06/17

Media for (AGL)

Presenter: Andrew Newland, Chief Executive

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Preclinical Study Presented At Tumor Boston Summit

RNS Number: 6533L Angle PLC 20 July 2017 For immediate release 20 July 2017 ANGLE plc ("the Company") PRECLINICAL STUDY USING PARSORTIX PRESENTED AT TUMOR MODELS BOSTON SUMMIT Parsortix system demonstrates capabilities for use in cancer drug research ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy co...

Notice of Results

RNS Number: 3024K Angle PLC 06 July 2017 For Immediate Release 6 July 2017 ANGLE plc ("ANGLE" or "the Company") Notification of Preliminary Results and Webcast ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 30 April 2017 on Thursday 27 July 2017. A meeting...

ANGLE confirms successful data in cancer studies

ANGLE , a world-leading liquid biopsy company, has announced positive headline results from 400 patient pelvic mass stu...

Successful Headline Data in Ovarian Cancer Studies

RNS Number: 0003K Angle PLC 04 July 2017 For immediate release 4 July 2017 ANGLE plc ("the Company") ANGLE REPORTS SUCCESSFUL HEADLINE DATA IN US AND EUROPEAN OVARIAN CANCER STUDIES IN 400 PATIENTS Parsortix blood test demonstrates potential to out-perform current standard of care in identifying ovarian cancer ANGL...

FTSE lower amid ex-divs ahead of BoE rate call

London shares opened lower as a lengthy list of ex-dividend stocks undoubtedly weighed and as investors looked to the mid...

Parsortix breakthrough in prostate cancer

RNS Number: 1286I Angle PLC 15 June 2017 For immediate release 15 June 2017 ANGLE plc ("the Company") PARSORTIX BREAKTHROUGH DELIVERS RARE BLOOD CELL DISCOVERY IN PROSTATE CANCER Barts Cancer Institute study finds rare type of cell in cancer patient blood linked to survival Use of Parsortix identifies patients that are 10 times m...

Parsortix success reported at ASCO, says ANGLE

ANGLE has announced that researchers have presented successful results from their work using the company's Parsortix ...

Success with Parsortix in Colorectal Cancer

RNS Number: 0859H Angle PLC 05 June 2017 For immediate release 5 June 2017 ANGLE plc ("the Company") SUCCESS WITH PARSORTIX IN COLORECTAL CANCER Clinically relevant results presented at ASCO 2017 cancer conference Demonstrates use of the Parsortix system to predict resistance to cancer drugs ANGLE plc (AIM:AGL OTCQX:ANPCY), the s...

Fundamental DataMore

Dividend yield0 %

Equity Research (AGL)

edison investment research
This morning Angle reported initial results from its two lead clinical trials with Parsortix, a liquid biopsy system. The two studies ran in parallel in Europe (ANG-001) and the US (ANG-003) and...
edison investment research
Yesterday Angle announced that researchers from Queen Mary University of London's Barts Cancer Institute (BCI) published new data further supporting Angle’s Parsortix system for use in prostate...
Toople* (TOOP.L) 3.25p £3.25m The provider of bespoke telecom services to UK SMEs, announced that it received a strong response from investors pursuant to Initial C l o s i n g o f t h e...

Latest discussion posts More

  • RNS

    So our system is the best - and the price drops 6%.
  • Re: How strong is AGL's protected competitiv...

    I think a lot of people also overlook that there is less than 75 m shares in issue so once the commercialisation really gets rolling with ongoing long term income 'per test' ...
  • How strong is AGL's protected competitive moat?

    I had some concerns about this. As I said in an earlier post, this is not a drug which is waiting for years and years to get recognition and permission for application. On ...
    claude reins

Users' HoldingsMore

Users who hold Angle also hold..
RDS 'B'13%

Codes & Symbols